StreetInsider.com News Articles

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development

Fri, 19 Jun 2026 18:00:00 -0400

Also Announces Appointment of Mr. Dave Antony as CFO

VANCOUVER, BC / ACCESS Newswire / June 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN:A3EKSZ) ("Onco" or the "Company") announced the successful completion of a 300-gram scale-up batch of A83B4C63, the active pharmaceutical ingredient ("API") underpinning the Company'sproprietary drug candidate, ONC010 (the "PNKP Inhibitor Technology").

The completed 300g scale-up batch forms part of Dalton Pharma Services' Process Optimization and Intermediate Scale-Up Program and follows the successful completion of process development activities and multiple intermediate scale-up campaigns. The program was designed to demonstrate manufacturing reproducibility,

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development

Fri, 19 Jun 2026 18:00:00 -0400

Also Announces Appointment of Mr. Dave Antony as CFO

Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization

Tue, 16 Jun 2026 18:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 16, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news release dated November 18, 2025, the completion of its pilot project with Kuano Ltd. ("Kuano"), supporting the continued advancement of Onco's PNKP Inhibitor Technology (also known as ONC010) through advanced AI-enabled and quantum-based computational approaches.

Kuano has completed the project and delivered findings derived from molecular modelling and advanced computational analytics that strengthen Onco's understanding of how its PNKP inhibitor and related analogs may interact

Onco-Innovations Completes Project with Kuano, Using Their Quantum-Based Platform to Deliver Insights for PNKP Inhibitor Technology Optimization

Tue, 16 Jun 2026 18:00:00 -0400

Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology

Tue, 09 Jun 2026 18:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 9, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce the initiation of process development and intermediate[1] scale-up activities for A83B4C63, the Company's active pharmaceutical ingredient (API) in the Company's proprietary drug candidate, ONC010 (the "PNKP Inhibitor Technology"). This milestone marks an important step in advancing the Company's chemistry, manufacturing, and controls (CMC) strategy as it progresses toward IND-enabling studies and planning for First-in-Human clinical evaluation. The program will focus on optimizing synthetic processes, improving yield and reproducibility

Onco-Innovations Announces Initiation of API Process Development and Intermediate Scale-Up Program for its Proprietary PNKP Inhibitor Technology

Tue, 09 Jun 2026 18:00:00 -0400

Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program

Fri, 05 Jun 2026 18:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / June 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has entered into a non-binding Letter of Intent ("LOI") with Nanosoft Polymers ("Nanosoft"), a biotechnology-focused polymer company, as an initial step toward negotiating a services agreement related to polymer process development, analytical characterization, and drug formulation optimization activities for the Company's exclusively licensed PNKP Inhibitor Technology, ONC010. The LOI is non-binding, and there is no certainty that a services agreement will be entered into.

Nanosoft specializes in

Onco-Innovations Signs LOI with Nanosoft Polymers to Advance Polymer and Drug Delivery Development for the ONC010 Program

Fri, 05 Jun 2026 18:00:00 -0400

Nanosoft specializes in

Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program

Tue, 02 Jun 2026 18:00:00 -0400

Also Announces Marketing Program

VANCOUVER, BC / ACCESS Newswire / June 2, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H) (WKN: A3EKSZ) ("Onco" or the "Company") announces, further to its news release dated May 19, 2026, the successful advancement of kilogram-scale manufacturing activities for the B4 precursor component supporting the development of ONC010, the Company's lead nanoparticle-formulated Polynucleotide Kinase Phosphatase (PNKP) Inhibitor Technology.

The milestone was achieved through the Company's ongoing chemistry, manufacturing and controls (CMC) collaboration with Dalton Pharma Services and represents an important step in scaling the manufacturing process required to support future

Onco-Innovations Advances 1kg Scale-Up of B4 Precursor Supporting ONC010 Manufacturing and Clinical Development Program

Tue, 02 Jun 2026 18:00:00 -0400

Also Announces Marketing Program

Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program

Tue, 19 May 2026 18:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 19, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce, further to its news release dated April 28, 2026, continued progress in the intermediate¹ scale-up and process development activities for the A83 and B4 precursor components supporting the Company's lead oncology program, ONC010, a novel nanoparticle-formulated PNKP inhibitor currently advancing through IND-enabling development.

The work is being conducted through the Company's integrated chemistry, manufacturing and controls (CMC) development program in collaboration with Dalton Pharma Services and forms part of

Onco-Innovations Reports Continued Advancement of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for ONC010 Development Program

Tue, 19 May 2026 18:00:00 -0400

The work is being conducted through the Company's integrated chemistry, manufacturing and controls (CMC) development program in collaboration with Dalton Pharma Services and forms part of

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate

Fri, 15 May 2026 18:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 15, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has advanced its Chemistry, Manufacturing and Controls ("CMC") development program through the initiation of analytical method validation activities for assay, related substances, and residual solvents for A83B4C63, the active pharmaceutical ingredient ("API") for Onco's exclusively-licensed PNKP Inhibitor Technology, ONC010. These validation activities are designed to ensure the Company can consistently measure what is in the drug, confirm it meets quality standards, and demonstrate that manufacturing is reliable,

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate

Fri, 15 May 2026 18:00:00 -0400

Onco-Innovations Announces Initiation of Research Collaboration within PROmAI

Tue, 12 May 2026 18:00:00 -0400

Aim is to Predict Oncology Outcomes using Multimodal Artificial Intelligence

VANCOUVER, BC / ACCESS Newswire / May 12, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco") is pleased to announce that its wholly-owned subsidiary, Inka Health Corp. (together with Onco, the "Company"), has entered into a research collaboration with AstraZeneca, a global biopharmaceutical company. This work forms part of the Company's PROmAI program, short for Predicting Oncology Outcomes using Multimodal Artificial Intelligence, focused on advancing predictive modelling capabilities in oncology through multimodal artificial intelligence.

The work centers on the development and evaluation

Onco-Innovations Announces Initiation of Research Collaboration within PROmAI

Tue, 12 May 2026 18:00:00 -0400

Aim is to Predict Oncology Outcomes using Multimodal Artificial Intelligence

The work centers on the development and evaluation

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology

Fri, 08 May 2026 18:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 8, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announces that Nucro-Technics Inc. ("Nucro-Technics"), a Toronto-based contract research organization collaborating with Onco on preclinical development, has commenced advanced bioanalytical work in support of the Company's ongoing non-GLP¹ pharmacokinetic (PK) and biodistribution animal model study involving A83B4C63, the active pharmaceutical ingredient ("API") for Onco's exclusively-licensed PNKP Inhibitor Technology (the "Technology"). The initiation of this work represents a significant step forward in translating the Technology from early-stage discovery into a development-ready therapeutic candidate.

Nucro-Technics has

Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology

Fri, 08 May 2026 18:00:00 -0400

Nucro-Technics has

Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation

Tue, 05 May 2026 18:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / May 5, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") is pleased to announce that Inka Health Corp. ("Inka Health"), the Company's wholly owned subsidiary, has started a collaborative research agreement (the "Agreement" or "Project" or "Work") with GlaxoSmithKline LLC ("GSK"). Under the Agreement, Inka Health and GSK intend to collaborate to develop real-world data-driven methodologies aimed at improving the transportability of oncology clinical trial results across broader patient populations, geographies, and healthcare settings, with a view to helping to make clinical evidence

Onco-Innovations Announces Inka Health Collaborative Research to Advance Oncology Evidence Generation

Tue, 05 May 2026 18:00:00 -0400

Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

Fri, 01 May 2026 18:00:00 -0400

Also Announces Extension of IR Program

VANCOUVER, BC / ACCESS Newswire / May 1, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt: W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that its manufacturing partner, Dalton Pharma Services ("Dalton"), has advanced into the next phase of intermediate-scale process development and scale-up for the Company's proprietary PNKP inhibitor technology. This next phase of work includes an expanded scale-up of precursor A83 to approximately 1,560 grams and the initiation of a multi-kilogram (2 kg) non-GMP synthesis of A83B4C63 as part of the Company's ongoing

Onco-Innovations Expands Manufacturing Scale-Up of Its PNKP Inhibitor Technology with Dalton Pharma Services, Advancing Multi-Kilogram Non-GMP Synthesis to Support IND-Enabling Studies

Fri, 01 May 2026 18:00:00 -0400

Also Announces Extension of IR Program

Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program

Tue, 28 Apr 2026 18:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 28, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN:A3EKSZ) ("Onco" or the "Company") announced, further to its news release dated April 21, 2026, the successful scale-up of key intermediates¹ A83 and B4, representing an advancement in the Company's chemistry, manufacturing and controls (CMC) program supporting its lead nanoparticle-based PNKP inhibitor drug candidate, ONC010 (also referred to as PNKP Inhibitor Technology). These intermediates are essential components in the synthesis of A83B4C63, the active pharmaceutical ingredient (API) utilized in the Company's proprietary nanoparticle formulation of ONC010.

Conducted in collaboration

Onco-Innovations Announces Successful Scale-Up of Key Materials Used in the Synthesis of its Active Pharmaceutical Ingredient for its PNKP Inhibitor Technology Program

Tue, 28 Apr 2026 18:00:00 -0400

Conducted in collaboration

Onco-Innovations Advances Polymer Testing as It Moves Its PNKP Inhibitor Technology Toward IND-Enabling Studies

Thu, 23 Apr 2026 18:00:00 -0400

VANCOUVER, BC / ACCESS Newswire / April 23, 2026 / Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H, WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has advanced an analytical method used to measure and control a key polymer within its PNKP Inhibitor Technology (the "Technology"), supporting continued formulation development and scale-up as the Company advances toward its goal of clinical manufacturing. This work is intended to help ensure consistency in the Company's delivery system as it progresses toward IND-enabling studies and plans for future Phase 1 clinical activities.

The analytical method, known